The issue, which some experts argue is inevitable, occurs when drugmakers stamp out pills on the same machine that is used to stamp out a different pill.
Drug cross-contamination is rampant, but the amount of cross-contaminated drugs that have been prescribed to Americans remains unclear because drugmakers largely handle the matter themselves, supervisors are often lax on cross-contamination guidelines and employees are fallible, current and former FDA inspectors told Bloomberg.
The FDA determines how often it will inspect drug manufacturing plants based on its calculation of risk associated with each facility, so many plants go years without inspections.
Comprehensive independent testing is difficult to achieve because inspectors would need to know which substances they’re looking for, and drugmakers don’t disclose which products they make at which factories.
When a routine test reveals an inappropriate substance in a drug, drugmakers often don’t test them for cross-contamination. If they say their cleaning policies are rigorous and they haven’t recorded elevated levels of drug substance left behind, they deem cross-contamination testing to be unnecessary, current and former FDA inspectors told Bloomberg.
The inspectors also said the FDA has not routinely collected samples of drugs for cross-contamination testing after red flags are found.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
